23andMe relaunches some DNA-based health tests after extended dispute with FDA

Genetic testing company 23andMe is reintroducing some health screening tools that federal regulators forced off the market more than two years ago, due to concerns about their accuracy and interpretation by customers. The Google-backed company said Wednesday it will again offer 35 tests that tell users whether they carry genetic mutations for rare diseases like cystic fibrosis, which can be passed from parents to children. The relaunch comes as the Silicon Valley company works to mend its relationship with the Food and Drug Administration and medical experts who have criticized the company's direct-to-consumer approach.